Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.ACET · Entity 6860 | Director | June 21, 2026 | June 23, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 21, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.10 · Expires 2036-06-20 | Direct | 4,200 |
Reported balance
After 2026-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-21 · Grant · Acquired 4,200 · Balance 4,200 F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors.
Scholar Rock Holding Corp
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,759 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Sale · Disposed 2,988 · Balance 36,759 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.970 to $53.965, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3: Consists of 23,958 shares of common stock and 12,801 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 34,322 |
Reported balance
After 2026-07-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-01 · Sale · Disposed 2,437 · Balance 34,322 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.967 to $54.815, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5: Consists of 21,521 shares of common stock and 12,801 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 34,301 |
Reported balance
After 2026-07-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-07-01 · Sale · Disposed 21 · Balance 34,301 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.860 to $55.016, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F7: Consists of 21,500 shares of common stock and 12,801 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs).
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.970 to $53.965, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Consists of 23,958 shares of common stock and 12,801 RSUs.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.967 to $54.815, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: Consists of 21,521 shares of common stock and 12,801 RSUs.
F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.860 to $55.016, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F7: Consists of 21,500 shares of common stock and 12,801 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 21 | $54.96 | $1,154.25 |
DisclosureSEC source: 0001193125-26-296245 · ownership.xml · nonDerivative · entry 3 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,301 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.860 to $55.016, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F7 · balance_after: Consists of 21,500 shares of common stock and 12,801 RSUs. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,437 | $54.25 | $132,213.59 |
DisclosureSEC source: 0001193125-26-296245 · ownership.xml · nonDerivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,322 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.967 to $54.815, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 21,521 shares of common stock and 12,801 RSUs. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,988 | $53.56 | $160,036.68 |
DisclosureSEC source: 0001193125-26-296245 · ownership.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,759 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 20, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $52.970 to $53.965, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 23,958 shares of common stock and 12,801 RSUs. Read SEC document |
| June 21, 2026 Filed Jun 23, 2026 20:26 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 4,200 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001983850-26-000001 · ownership.xml · derivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 Underlying: Common Stock · 4,200 shares Expires 2036-06-20 F1 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:49 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 4,310 | $0.00 Strike: $45.33 | $0.00 |
DisclosureSEC source: 0001104659-26-071425 · tm2617049-2_4seq1.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 4,310 shares Expires 2036-06-04 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:49 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 6,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071425 · tm2617049-2_4seq1.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,747 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 26,201 shares of common stock and 13,546 RSUs. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 280 | $44.63 | $12,497.63 |
DisclosureSEC source: 0001983850-25-000005 · form4-12182025_041201.xml · nonDerivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,908 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.39 to $45.23, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 14,844 shares of common stock and 18,064 RSUs. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 726 | $43.88 | $31,854.05 |
DisclosureSEC source: 0001983850-25-000005 · form4-12182025_041201.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,188 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.39 to $44.38, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 15,124 shares of common stock and 18,064 RSUs. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 76 | $33.20 | $2,522.92 |
DisclosureSEC source: 0001983850-25-000003 · form4-09172025_040903.xml · nonDerivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,914 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units ("RSUs"). F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.73, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 13,614 shares of common stock and 20,300 RSUs. Read SEC document |
| September 16, 2025 Filed Sep 17, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 930 | $32.48 | $30,202.77 |
DisclosureSEC source: 0001983850-25-000003 · form4-09172025_040903.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,990 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.85 to $32.83, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 13,690 shares of common stock and 20,300 RSUs. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 54 | $32.53 | $1,756.56 |
DisclosureSEC source: 0001415889-25-017540 · form4-06172025_040613.xml · nonDerivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,920 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units ("RSUs"). F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.43 to $32.78, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 12,385 shares of common stock and 22,535 RSUs. Read SEC document |
| June 16, 2025 Filed Jun 17, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,977 | $31.96 | $95,131.82 |
DisclosureSEC source: 0001415889-25-017540 · form4-06172025_040613.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,974 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units ("RSUs"). F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.44 to $32.41, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 12,439 shares of common stock and 22,535 RSUs. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-086157 · ownership.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2035-06-10 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:05 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086157 · ownership.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,800 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 9,206 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001104659-25-052472 · tm2516084-3_4seq1.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,206 Underlying: Common Stock · 9,206 shares Expires 2035-05-22 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:41 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 7,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-052472 · tm2516084-3_4seq1.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,951 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2026 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 14,671 shares of Common Stock and 23,280 RSUs. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:00 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 1,006 | $34.42 | $34,626.92 |
DisclosureSEC source: 0001415889-25-008593 · form4-03192025_050301.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,319 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units. F2 · balance_after: Consists of 8,680 shares of common stock and 21,639 RSUs. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 70,200 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0000950170-24-100178 · ownership.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2033-07-09 F1 · derivative.exercise_price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 21, 2024 Filed Aug 23, 2024 20:07 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0000950170-24-100178 · ownership.xml · derivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,200 shares Expires 2033-07-09 F1 · kind: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: Effective August 21, 2024, the Issuer's Board of Directors approved a rescission of the August 2023 stock option repricing for certain non-employee directors of the Issuer. All of the affected stock options have been reverted to their original exercise price as established at the time of the grant. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001415889-24-018645 · form4-07012024_090712.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-06-27 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018645 · form4-07012024_090712.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,325 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 2,980 shares of common stock and 28,345 RSUs. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:04 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 26,400 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0000950170-24-070577 · ownership.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires 2034-06-04 F2 · derivative.exercise_date: These shares shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:04 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070577 · ownership.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 F1 · shares: The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. Read SEC document |
| April 09, 2024 Filed Apr 12, 2024 00:26 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 35,767 | $0.00 Strike: $14.82 | $0.00 |
DisclosureSEC source: 0001415889-24-010735 · form4-04122024_120418.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,767 Underlying: Common Stock · 35,767 shares Expires 2034-04-09 F2 · derivative.exercise_date: Options to vest in monthly installments over three years following the date of appointment, with the next installment to vest on April 15, 2024 and each additional installment to vest monthly thereafter, subject to continued service to the Issuer through each such date. Read SEC document |
| April 09, 2024 Filed Apr 12, 2024 00:26 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 26,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010735 · form4-04122024_120418.xml · nonDerivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,825 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest in monthly installments over three years following the date of appointment, with the next installment to vest on April 15, 2024 and each additional installment to vest monthly thereafter, subject to continued service to the Issuer through each such date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:03 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 70,200 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-23-046090 · doc4.xml · derivative · entry 2 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2033-07-09 F3 · derivative.exercise_price: The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised. F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| August 14, 2023 Filed Aug 16, 2023 22:03 UTC | Adicet Bio, Inc. ACET · Entity 6860 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,200 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001209191-23-046090 · doc4.xml · derivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,200 shares Expires 2033-07-09 F1 · kind: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on July 10, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 20:30 UTC | Adicet Bio, Inc. ACET · Entity 6860 | GrantStock Option (Right to Buy) · Derivative | 70,200 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001209191-23-042018 · doc4.xml · derivative · entry 1 Peng Katie · CIK 0001983850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,200 Underlying: Common Stock · 70,200 shares Expires 2033-07-09 F1 · derivative.exercise_date: These shares shall vest in thirty-six (36) equal monthly installments beginning July 10, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.